Latest news with #KJ
New Straits Times
4 days ago
- Entertainment
- New Straits Times
#SHOWBIZ: KJ wins Hot FM's Bekpes Hot Clash of Champions
KUALA LUMPUR: ST Rosyam Mall became a buzzing arena yesterday as Hot FM hosted a special event, the Bekpes Hot Clash of Champions. The highlight of the day was a spirited exhibition boxing match where popular radio presenter KJ "The Panther" successfully defeated his opponent, Saiful "The Vampire" Merican. The event not only showcased thrilling action but also served as a platform to promote a healthy lifestyle and encourage interest in martial arts such as Muay Thai and boxing. Among the Hot FM personalities who took part were Fara "The Furious" Fauzana, AG "The Unseen", and Bidin Al Zaifa, who expertly compered the event. Special appearances were also made by celebrities, including Elizabeth Tan and national boxer Adli "The Golden Boy". In another exciting bout, AG fought Adli, which ended in a draw. The hand-wrestling match between Fara and Tan saw Tan emerge victorious with a 2-1 win. Attendees had the chance to win fantastic prizes, with an Umrah package sponsored by ST Rosyam Mall and RM500 cash among the main rewards for the winners. Hot FM's senior content director, Raja Khairil, said, "KJ has always been interested in boxing, and this was one of his dreams that we helped make come true. Even though it was just a friendly exhibition fight, Saiful and KJ took it seriously and made thorough preparations." Notable guests who attended the event included Media Prima Audio Chief Executive Officer Nazri Noran, as well as celebrities Datuk Aaron Aziz, DJ Fuzz, and Ammar Titan.
Sinar Daily
4 days ago
- Entertainment
- Sinar Daily
KJ defeats MMA champion Saiful Merican
KJ said he has known Saiful for a long time and described the opportunity to share the same ring with the national MMA athlete as a very meaningful moment. Hot FM radio announcer Khairy Jamaluddin defeated former world number one Muay Thai athlete Saiful Merican in a friendly match on Sunday. KLANG – The dream of Hot FM radio announcer Khairy Jamaluddin to step into the boxing ring finally came true when he defeated former world number one Muay Thai athlete Saiful Merican in a friendly match here on Sunday. Khairy, better known as KJ, expressed his gratitude after securing victory over the 37-year-old mixed martial arts (MMA) star during the Clash of Champion Hot FM event held at ST Rosyam Mart, Jalan Kebun. 'Since I was young, I've always loved boxing and grew up watching Muhammad Ali, Sugar Ray Leonard and Mike Tyson. 'I've always wanted to step into the boxing ring and I never expected to get this opportunity today (Sunday). 'To be able to test my strength against such a respected martial arts figure, Saiful Merican or Saiful 'The Vampire' Merican, is truly an honour,' he said. It is understood that the friendly boxing match between KJ and Saiful had been planned since last year. Further commenting, KJ said he has known Saiful for a long time and described the opportunity to share the same ring with the national MMA athlete as a very meaningful moment. 'In the first two minutes, he gave me some leeway, but when he punched, he really punched hard,' KJ said jokingly. KJ also expressed appreciation to everyone involved in making the match a success, including his coach and his son, Jibriel Ali, who served as his corner man in the ring. Apart from the main bout between KJ and Saiful, more than 300 spectators were also entertained by another boxing match between fellow Bekfes Hot FM announcer AG and Adli Goldenboy, which ended in a draw. An arm wrestling showdown between announcer Fara Fauzana and singer Elizabeth Tan also drew attention, with Fara ultimately conceding defeat to Elizabeth's strength.
The Hill
23-07-2025
- Health
- The Hill
The FDA must be modernized for the era of personalized medicine
A baby named KJ was born in Philadelphia with an ultra-rare metabolic disorder that, under normal circumstances, would have required an organ transplant or been fatal. Instead, doctors sequenced KJ's genome and identified a unique mutation. Within six months, they designed and delivered a personalized CRISPR-based therapy — resulting in the first patient to be cured by a bespoke gene-editing treatment. A few years earlier, a young girl in Boston named Mila suffered from a fatal neurodegenerative disease. In just 10 months, a team of doctors designed, developed and synthesized a one-of-a-kind drug just for her, this time using an antisense oligonucleotide therapy that slowed the progression of her disease. These are more than medical miracles. They are proof that it is now possible to tailor medicines to a single person's genetic code. What is missing is a regulatory framework to scale these one-off breakthroughs into a new standard of care. Globally, more than 50 million children suffer from rare genetic diseases — and nearly one in five will die before the age of five. Even children with the same diagnosis can carry different genetic mutations, meaning a one-size-fits-all drug may be ineffective or impossible to make. The problem is our healthcare system isn't designed or incentivized to develop drugs for individual patients. The good news is that science and technology have caught up. We can now sequence a genome for under $100. Artificial intelligence models can design mutation-specific therapies in days and RNA-based treatments can be manufactured in weeks. Operation Warp Speed showed our ability to distribute advanced therapies at scale. And with wearables and digital health tools, we can monitor children's physiological response in real-time, both before and after treatment. The FDA's current approval framework is nearly a century old. It was originally designed to regulate mass-produced drugs for large populations. While there have been reforms since then, most have been incremental and tailored to conventional pharmaceutical development. The current process treats personalized medicines — especially 'N-of-1' therapies — as individual research trials. This approach is time-consuming, expensive and not scalable for the millions of patients who could benefit. Rare disease doesn't just affect patients, it drains families and their communities. Parents leave the workforce to become full-time caregivers. Families travel across the country for access to specialists. Experimental treatments, hospital stays, lost wages and uncovered expenses can bankrupt a family before a diagnosis is even confirmed. In many cases, the child's condition continues to deteriorate while waiting for a diagnosis or cure. The cumulative damage is incalculable. Thanks to advances in genomics, AI, synthetic biology and preclinical testing, personalized therapies are becoming more cost-effective and scalable. For example, the FDA's recent roadmap to phase out mandatory animal testing opens the door to validating therapies using artificial organs or a patient's own cells — improving safety while cutting time and cost. America remains a global leader in the core breakthroughs that made Mila and KJ's treatments possible — from CRISPR gene editing to large language models trained on protein and RNA structures. But that lead is fragile. The FDA has taken steps in the right direction, including establishing a pathway for personalized CAR-T therapies and issuing draft guidance for ASO drugs. But guidance isn't enough. We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized therapeutics. Without it, researchers and companies will hesitate to invest time and resources into what feels like regulatory guesswork. As the FDA and the Department of Health and Human Services undergo what appear to be structural changes, this is a rare window to modernize regulation and secure America's position at the forefront of next-generation medicine. To turn personalized therapies into a new standard of care, the FDA can take a number of key steps. The agency should create a new regulatory pathway for bespoke therapeutics. N-of-1 drugs can't be evaluated using the traditional Phase 1-2-3 frameworks. We need an entirely new process-oriented framework that considers families, physicians, payers, regulators and industry alike. The FDA should establish a dedicated oversight body. A centralized group within the agency should review personalized therapeutics, set transparent safety and ethics standards and ensure rigorous tracking of outcomes. This will build consistency, speed and public trust. The agency should enable sustainable funding and reimbursement. Cost no longer needs to be the barrier. Clear regulatory rules will unlock investment, while reimbursement frameworks will ensure payers can cover these treatments responsibly. Absent this, safe and effective therapies may never reach patients. Every week matters for a child with a rare, degenerative condition. Acting now can turn scientific breakthroughs into a public health reality. If we wait, we risk letting outdated regulation stall progress — and watching the rest of the world move forward without us. The tools are here. The science is ready. All that's missing is a regulatory system built for the future of medicine that doesn't treat individualized care as an exception, but as the new standard. Nessan Bermingham is an operating partner at Khosla Ventures, where he invests in genetic medicines and AI drug discovery and development. He is also the founding CEO of Intellia Therapeutics, the founder and chairman of Korro Bio, and a board member of EveryONE Medicines.
The Star
21-07-2025
- Entertainment
- The Star
Singapore's Chiral Comics partners Archie Comics for exclusive SG60 book cover
The SG60 exclusive variant cover will be limited to 300 copies worldwide. - Chiralcomics/Instagram via ST/ANN SINGAPORE: Home-grown outfit Chiral Comics has teamed up with American comic book publisher Archie Comics to launch a Singapore-themed variant cover for the first issue of Betty & Veronica: Summer Fun In The Sun. The exclusive book cover – where main character Archie dons an 'I Love SG' shirt while his best friend Jughead munches on durian – features the characters from the popular franchise (1942 to present) exploring the country's iconic Gardens by the Bay. It is limited to 300 copies worldwide. Priced at $25.55 each, pre-orders started on July 19 at Select Singapore comics retailers like Kalibak Komiks and 1to3 Comics will also carry it. This SG60 book cover collaboration involves local comic artist Kang Jing (also known as KJ), who was the penciler and inker, and Italy-based freelance comic colourist Daniele Caramanico, who did the colouring. KJ established Chiral Comics, a Singapore-based art studio which specialises in comic book publishing and visual storytelling, in 2021, and reportedly started working on the Archie project in April 2025. The 31-year-old, who has been sketching anime characters since he was six, began his comics career in 2019. His debut series The World My Arena (2021 to 2022) has since been adapted into an animated video, and other notable works include bilingual webcomic series Save Me From Chloe (2021) and Zhao (2023), an original wuxia comic series. KJ has also worked on seven Star Wars-themed projects with Topps, an American trading card manufacturer. And in 2024, he illustrated a Singapore-themed variant cover featuring the Singapore skyline for the Mighty Morphin Power Rangers #122 comic. All 525 copies released at comic convention Singapore Comic Con 2024 were sold out. - The Straits Times/ANN
AsiaOne
21-07-2025
- Entertainment
- AsiaOne
Singapore's Chiral Comics partners Archie Comics for exclusive SG60 book cover, Singapore News
SINGAPORE - Home-grown outfit Chiral Comics has teamed up with American comic book publisher Archie Comics to launch a Singapore-themed variant cover for the first issue of Betty & Veronica: Summer Fun In The Sun. The exclusive book cover - where main character Archie dons an "I Love SG" shirt while his best friend Jughead munches on durian - features the characters from the popular franchise (1942 to present) exploring the country's iconic Gardens by the Bay. It is limited to 300 copies worldwide. Priced at $25.55 each, pre-orders started on July 19 at Select Singapore comics retailers like Kalibak Komiks and 1to3 Comics will also carry it. This SG60 book cover collaboration involves local comic artist Kang Jing (also known as KJ), who was the penciler and inker, and Italy-based freelance comic colourist Daniele Caramanico, who did the colouring. KJ established Chiral Comics, a Singapore-based art studio which specialises in comic book publishing and visual storytelling, in 2021, and reportedly started working on the Archie project in April 2025. The 31-year-old, who has been sketching anime characters since he was six, began his comics career in 2019. His debut series The World My Arena (2021 to 2022) has since been adapted into an animated video, and other notable works include bilingual webcomic series Save Me From Chloe (2021) and Zhao (2023), an original wuxia comic series. KJ has also worked on seven Star Wars-themed projects with Topps, an American trading card manufacturer. And in 2024, he illustrated a Singapore-themed variant cover featuring the Singapore skyline for the Mighty Morphin Power Rangers #122 comic. All 525 copies released at comic convention Singapore Comic Con 2024 were sold out. [embed] [embed] [[nid:697039]] This article was first published in The Straits Times . Permission required for reproduction.
